These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 10064014)

  • 1. The relations of major platelet receptor expression during myocardial infarction. Monitoring efficacy of GPIIb/IIIa inhibitors by measuring P-selectin?
    Serebruany VL; Gurbel PA
    Thromb Haemost; 1999 Feb; 81(2):314-6. PubMed ID: 10064014
    [No Abstract]   [Full Text] [Related]  

  • 2. Reteplase but not alteplase affects early soluble PECAM-1 and P-selectin release in patients with acute myocardial infarction.
    Gurbel PA; Dalesandro MR; Serebruany VL
    Thromb Haemost; 1998 Oct; 80(4):725. PubMed ID: 9799011
    [No Abstract]   [Full Text] [Related]  

  • 3. [Thrombolytic therapy for acute myocardial infarct].
    Nordt TK; Bode C
    Internist (Berl); 2001 May; 42(5):659-64. PubMed ID: 11400573
    [No Abstract]   [Full Text] [Related]  

  • 4. [Reperfusion after acute myocardial infarct with fibrinolytic therapy o combination reduced fibrinolytic therapy and a glycoprotein IIb/IIIa inhibitor: the GUSTO V study].
    Franzosi MG
    Ital Heart J Suppl; 2001 Sep; 2(9):1034-6. PubMed ID: 11675828
    [No Abstract]   [Full Text] [Related]  

  • 5. Platelet GPIIb/IIIa receptor blockers for failed thrombolysis in acute myocardial infarction, alone or as adjunct to other rescue therapies.
    Mahadevan VS; McCarty D; Adgey AA
    Eur Heart J; 2002 Oct; 23(19):1490-1. PubMed ID: 12242068
    [No Abstract]   [Full Text] [Related]  

  • 6. Thrombolytic therapy: new dimensions 2009.
    Guha S; Mukherjee S; Hema MB
    Indian Heart J; 2009; 61(5):415-21. PubMed ID: 20635755
    [No Abstract]   [Full Text] [Related]  

  • 7. Increased baseline levels of platelet P-selectin, and platelet-endothelial cell adhesion molecule-1 in patients with acute myocardial infarction as predictors of unsuccessful thrombolysis.
    Gurbel PA; Serebruany VL; Shustov AR; Dalesandro M; Gumbs CI; Grablutz LB; Bahr RD; Ohman EM; Topol EJ
    Coron Artery Dis; 1998; 9(7):451-6. PubMed ID: 9822864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of tirofiban for failed thrombolysis during acute myocardial infarction.
    Vetrano A; Carotenuto R; Corsini F; Schioppa M; Martone A; Melorio S; Sideri F; Romano S; Chieffo C; Corsini G
    Am J Cardiol; 2004 Apr; 93(7):914-6. PubMed ID: 15050497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble vascular cell adhesion molecule-1 and E-selectin in patients with acute myocardial infarction treated with thrombolytic agents.
    Gurbel PA; Serebruany VL
    Am J Cardiol; 1998 Mar; 81(6):772-5. PubMed ID: 9527091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycoprotein IIb/IIIa antagonist and fibrinolytic agents: new therapeutic regimen for acute myocardial infarction.
    Patel VB; Moliterno DJ
    J Invasive Cardiol; 2000 Mar; 12 Suppl B():8B-15B. PubMed ID: 10731294
    [No Abstract]   [Full Text] [Related]  

  • 11. Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion.
    Straub S; Junghans U; Jovanovic V; Wittsack HJ; Seitz RJ; Siebler M
    Stroke; 2004 Mar; 35(3):705-9. PubMed ID: 14752128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis].
    Ottani F; Bresciani B; La Vecchia L; Favero L; Fontanelli A; Galvani M
    Ital Heart J Suppl; 2002 May; 3(5):544-54. PubMed ID: 12064194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombolytic therapy.
    Goldhaber SZ
    Adv Intern Med; 1999; 44():311-25. PubMed ID: 9929714
    [No Abstract]   [Full Text] [Related]  

  • 14. Reteplase set to enter thrombolytic market.
    Am J Health Syst Pharm; 1997 Jan; 54(1):12. PubMed ID: 9117779
    [No Abstract]   [Full Text] [Related]  

  • 15. Facilitation of thrombolysis in acute myocardial infarction.
    Gambhir DS
    Indian Heart J; 1999; 51(5):486-8. PubMed ID: 10721636
    [No Abstract]   [Full Text] [Related]  

  • 16. New directions in thrombolytic therapy.
    Toombs CF
    Curr Opin Pharmacol; 2001 Apr; 1(2):164-8. PubMed ID: 11714091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Disappointments and trends].
    Heinzl S
    Med Monatsschr Pharm; 1997 Oct; 20(10):263. PubMed ID: 9411176
    [No Abstract]   [Full Text] [Related]  

  • 18. [Tissue-type plasminogen activator and pro-urokinase--new fibrinolytic agents in the treatment of myocardial infarction].
    Czyrski J
    Wiad Lek; 1989 Apr; 42(7):450-2. PubMed ID: 2516932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newer thrombolytic drugs for acute myocardial infarction.
    Reddy DS
    Indian J Exp Biol; 1998 Jan; 36(1):1-15. PubMed ID: 9536645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the alpha-subunit 326GRV sequence in the surface expression of fibrinogen and vitronectin receptors.
    Ferrer M; Ayuso MS; Butta N; Parrilla R; González-Manchón C
    Am J Physiol; 1998 Nov; 275(5):C1239-46. PubMed ID: 9814972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.